Sign in

    Kathryn Haviland

    President and Chief Executive Officer at Blueprint Medicines Corp
    Board
    Since April 4, 2022
    Age
    48 years
    Education
    Holds a B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University and an M.B.A. from Harvard Business School.
    Tenure
    Joined BPMC in 2016 as Chief Business Officer, served as Chief Operating Officer from 2019 to April 3, 2022, and became President and CEO on April 04, 2022.

    Also at Blueprint Medicines Corp

    DD
    Debra Durso-Bumpus
    Chief People Officer
    PL
    Philina Lee
    Chief Commercial Officer
    AH
    Ariel Hurley
    Senior Vice President, Finance and Principal Accounting Officer

    About

    Kathryn Haviland is a seasoned executive with extensive experience in the biopharmaceutical industry. She joined Blueprint Medicines Corporation in 2016, initially serving as Chief Business Officer, before advancing to the role of Chief Operating Officer and then President and Chief Executive Officer on April 04, 2022.

    Throughout her tenure at BPMC, she has played a pivotal role in guiding the company through significant organizational transitions, demonstrating expertise in corporate strategy, financial management, and business development.

    Beyond her professional responsibilities at BPMC, she holds strong educational credentials with a B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University and an M.B.A. from Harvard Business School, which have bolstered her analytic and strategic capabilities.

    $BPMC Performance Under Kathryn Haviland

    Past Roles

    OrganizationRoleDate RangeDetails
    Blueprint Medicines Corporation (BPMC) Chief Operating Officer 2019–2022 Served in this role prior to her appointment as President and CEO
    Blueprint Medicines Corporation (BPMC) Chief Business Officer 2016–2019 Held this position before transitioning to COO
    Idera Pharmaceuticals, Inc. Vice President, Rare Diseases and Oncology Program Leadership 2014–2015 Idera is focused on oncology and inflammation (now Aceragen, Inc.)
    Sarepta Therapeutics, Inc. Head of Commercial Development 2012–2014 Focused on rare diseases
    PTC Therapeutics, Inc. Executive Director of Commercial Development 2007–2012 Focused on small molecule drugs and gene therapy
    Genzyme Corporation Various corporate development and project management roles 2005–2007 Now a subsidiary of Sanofi

    External Roles

    OrganizationRoleDate RangeDetails
    Fulcrum Therapeutics, Inc. Chairperson and member of the Audit and Nominating and Corporate Governance Committees Since 2018 N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$782,250 AnnualFixed annual salary for 2023
    All Other Compensation$13,200 Per 401(k) matching contribution scheduleDollar value of matching contributions under the company’s 401(k) plan
    Termination & Change-in-Control CompensationVaries (up to $18,508,534) Upon termination or change-in-control eventsIncludes severance payments, cash incentive payments, health care continuation, and acceleration of equity vesting under different scenarios

    Performance Compensation

    Data from  FY 2023

    Annual Performance-Based Cash Incentives for 2023

    MetricValueDetails
    Target Payout ($)$625,800 80% of base salary; set as the target for performance-based cash incentive
    Maximum Payout ($)$938,700 Capped at 150% of the target payout
    ThresholdN/A Not applicable for performance-based cash payments
    Performance Weight (%)50% Relative weighting for corporate performance goals
    Evaluation PeriodCalendar Year 2023 Performance measured over 2023 based on corporate financial and operational results
    Key Performance MetricsVarious Includes global product revenue targets for AYVAKIT, global total revenue, achieving an operating loss equal to or better than 2022, and specific launch/approval milestones (e.g., FDA approval and EU CHMP positive opinion for indolent SM)
    Grant DateMarch 1, 2023 Grant date with compensation committee approval on February 15, 2023
    Vesting/Payment ConditionNo vesting; Cash payout Cash incentive paid if Kathryn remains employed through the bonus payment date
    Actual Cash Incentive Payment ($)$719,670 Reflects the achievement of the set corporate performance goals

    Additional Details

    • The performance compensation is solely based on corporate performance goals; there are no individual performance metrics applicable for the CEO.
    • The bonus structure does not involve vesting, as it is a cash payout determined after the evaluation period.